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The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities.
We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-
dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.
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Imatinib mesylate (Gleevec, formerly STI571, Novartis, Basel,
Switzerland) is a selective inhibitor of the tyrosine kinase family
including the oncogenes Abl and Kit as well as the platelet-derived
growth factor receptor (PDGF-R). Owing to its mechanisms of
action, imatinib has been used successfully in chronic myelogen-
ous leukaemia (CML) and in gastrointestinal stromal tumours
(GIST). Dose-escalation studies proved imatinib as a well-tolerated
oral drug with rare dose-limiting toxicities (Druker et al, 2001).
Nevertheless, severe cutaneous side effects have been reported,
leading to a cessation of imatinib treatment in single cases
(Brouard and Saurat, 2001).
We here report on the first four patients being enrolled into a
clinical phase II study investigating imatinib as a second-line
therapy in advanced melanoma. The study’s rationale was based
on the well-known expression of c-kit as well as PDGF-R in
melanoma cell lines and tissues (Ohashi et al, 1996). Albeit the
patients’ clinical outcome still has to be awaited, we hereby provide
a first report of the noticeable strong and frequent cutaneous
adverse events.
DESCRIPTION OF CASES
All four patients received imatinib 400mg b.i.d. (800mgday
1)
after progression of melanoma disease under a first-line cytostatic
regimen was ascertained. Patients’ clinical data are summarized in
Table 1(A). Three of four patients showed moderate to strong
cutaneous reactions with a macular and/or urticarial pattern
within the first two weeks of therapy (Figure 1A, B). The
exanthema emanated from the face and trunk, and subsequently
afflicted the extremities. Other side effects were of mild to
moderate intensity including fluid retention, nausea, vomiting
and fatigue. As a result of the severity of skin reactions, 50% dose
adjustments became necessary in two of three patients. Addition-
ally, corticosteroids (methylprednisolon 60mgday
1 p.o.) were
given in one patient. The cutaneous eruptions regressed in all three
patients within 2–3 weeks. Thereafter, imatinib was again
escalated to 75% of the initial dose (600mgday
1) in patients 2
and 3, leading to a strong relapse of skin eruptions in both cases.
During the further course of treatment, imatinib was left at 50%
reduction (400mgday
1) in these two patients, resulting in no
further skin reactions.
HISTOLOGICAL ANALYSES AND DISCUSSION
A review of the literature revealed mild to moderate cutaneous
reactions as a common side effect to imatinib (Table 1(B)). In
contrast, severe skin reactions are rarely reported but, however,
occurred following high treatment doses of 600–1000mgday
1 as
used in a phase I trial in GIST (van Oosterom et al, 2001) as well as
in our ongoing study. Histological analyses of biopsy specimens of
lesional skin from patients 2 and 3 revealed loose mononuclear
cells infiltrating the dermis with a perivascular pattern (Figure 1C).
The upper dermis showed marked oedema and, remarkably, an
increased number of mast cells. Immunohistochemical analyses
using polyclonal goat-anti-human antibodies A4502 (DAKO,
Hamburg, Germany) recognising the c-kit gene product CD117
revealed a strong staining of mononuclear cells of the dermis
morphologically corresponding to mast cells (Figure 1D, E), as
additionally confirmed by Giemsa staining (Figure 1F). Human
mast cells, which express a functional c-kit receptor, are known to
be susceptible to tyrosine kinase inhibition by imatinib leading to
impaired proliferation as well as induction of apoptosis (Ma et al,
2002). Therefore, an enhanced proliferation of mast cells as
observed in our patients seems to be unlikely mediated via c-kit
inhibition on the mast cells themselves. We therefore suggest
imatinib to act as a dose-dependent inducer of chemoattractant
substances like, for example, cytokines and growth factors leading
to dermal mast cell accumulation. Nevertheless, the precise
mechanism of action needs to be further elucidated.
We conclude that imatinib acts as a dose-dependent inducer of
cutaneous adverse reactions with mainly mild reactivity to low or
intermediate doses (200–600mgday
1) but severe eruptions to
high doses (600–1000mgday
1) of the drug. Our findings should
stimulate further investigation of the cutaneous reaction profile to
imatinib. To avoid strong cutaneous adverse reactions, however, Received 17 January 2003; accepted 3 February 2003
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feasible.
REFERENCES
Brouard M, Saurat JH (2001) Cutaneous reactions to STI571. N Engl J Med
345: 618–619
Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B,
Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA,
Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic
S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and
safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med 347: 472–480
T
a
b
l
e
1
S
k
i
n
r
e
a
c
t
i
o
n
s
t
o
i
m
a
t
i
n
i
b
(
A
)
A
g
e
(
y
e
a
r
s
)
/
g
e
n
d
e
r
L
o
c
a
l
i
z
a
t
i
o
n
o
f
m
e
t
a
s
t
a
s
e
s
S
k
i
n
r
e
a
c
t
i
o
n
C
T
C
g
r
a
d
i
n
g
O
n
s
e
t
o
f
r
e
a
c
t
i
o
n
(
d
a
y
s
a
f
t
e
r
f
i
r
s
t
a
p
p
l
i
c
a
t
i
o
n
o
f
i
m
a
t
i
n
i
b
)
D
o
s
e
a
d
j
u
s
t
m
e
n
t
P
a
t
i
e
n
t
1
7
1
/
m
L
i
v
e
r
,
s
p
l
e
e
n
,
s
u
b
c
u
t
a
n
e
o
u
s
N
o
n
e
0
N
o
n
e
N
o
n
e
P
a
t
i
e
n
t
2
5
1
/
f
L
u
n
g
,
s
u
b
c
u
t
a
n
e
o
u
s
G
e
n
e
r
a
l
i
s
e
d
m
a
c
u
l
a
r
a
n
d
u
r
t
i
c
a
r
i
a
l
e
r
u
p
t
i
o
n
3
1
0
5
0
%
r
e
d
u
c
t
i
o
n
P
a
t
i
e
n
t
3
4
1
/
f
L
y
m
p
h
n
o
d
e
s
,
s
u
b
c
u
t
a
n
e
o
u
s
G
e
n
e
r
a
l
i
z
e
d
m
a
c
u
l
a
r
a
n
d
u
r
t
i
c
a
r
i
a
l
e
r
u
p
t
i
o
n
3
5
5
0
%
r
e
d
u
c
t
i
o
n
,
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
P
a
t
i
e
n
t
4
6
9
/
f
S
k
i
n
M
a
c
u
l
a
r
r
a
s
h
o
f
t
h
e
f
a
c
e
2
7
N
o
n
e
(
B
)
A
u
t
h
o
r
,
y
e
a
r
o
f
p
u
b
l
i
c
a
t
i
o
n
I
m
a
t
i
n
i
b
d
o
s
e
(
m
g
d
a
y

1
)
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
t
r
e
a
t
e
d
M
i
l
d
o
r
m
o
d
e
r
a
t
e
c
u
t
a
n
e
o
u
s
r
e
a
c
t
i
o
n
s
(
C
T
C
g
r
a
d
e
1
–
2
)
S
e
v
e
r
e
c
u
t
a
n
e
o
u
s
r
e
a
c
t
i
o
n
s
(
C
T
C
g
r
a
d
e
3
–
4
)
C
M
L
K
a
n
t
a
r
j
i
a
n
e
t
a
l
(
2
0
0
2
)
4
0
0
5
3
2
1
5
5
(
2
9
.
1
%
)
1
6
(
3
.
0
%
)
C
M
L
T
a
l
p
a
z
e
t
a
l
(
2
0
0
2
)
4
0
0
–
6
0
0
2
3
5
4
9
(
2
0
.
8
%
)
3
(
1
.
3
%
)
C
M
L
S
a
w
y
e
r
s
e
t
a
l
(
2
0
0
2
)
4
0
0
–
6
0
0
2
6
0
4
8
(
1
8
.
5
%
)
1
1
(
4
.
2
%
)
G
I
S
T
v
a
n
O
o
s
t
e
r
o
m
e
t
a
l
(
2
0
0
1
)
4
0
0
–
1
0
0
0
4
0
1
7
(
4
2
.
5
%
)
5
(
1
2
.
5
%
)
G
I
S
T
D
e
m
e
t
r
i
e
t
a
l
(
2
0
0
2
)
4
0
0
–
6
0
0
1
4
7
4
1
(
2
7
.
9
%
)
4
(
2
.
7
%
)
(
A
)
M
e
l
a
n
o
m
a
p
a
t
i
e
n
t
s
t
r
e
a
t
e
d
w
i
t
h
i
m
a
t
i
n
i
b
8
0
0
m
g
d
a
y

1
.
(
B
)
C
M
L
a
n
d
G
I
S
T
p
a
t
i
e
n
t
s
t
r
e
a
t
e
d
w
i
t
h
d
i
f
f
e
r
e
n
t
d
o
s
e
s
o
f
i
m
a
t
i
n
i
b
.
C
T
C
=
c
o
m
m
o
n
t
o
x
i
c
i
t
y
c
r
i
t
e
r
i
a
o
f
t
h
e
N
a
t
i
o
n
a
l
C
a
n
c
e
r
I
n
s
t
i
t
u
t
e
,
N
a
t
i
o
n
a
l
I
n
s
t
i
t
u
t
e
s
o
f
H
e
a
l
t
h
;
C
M
L
=
c
h
r
o
n
i
c
m
y
e
l
o
g
e
n
o
u
s
l
e
u
k
a
e
m
i
a
;
G
I
S
T
=
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
s
t
r
o
m
a
l
t
u
m
o
u
r
.
Figure 1 Photographs and photomicrographs of patient 3 at day 10 after
the onset of treatment with imatinib 800mgday
1.( A, B) Face and trunk
of the patient showing generalised macular and urticarial cutaneous
eruptions. (C) Haematoxylin–eosin staining of lesional skin revealing a
mononuclear infiltrate and marked oedema of the upper dermis;
magnification 1:200. (D, E) Immunohistochemical staining of lesional skin
showing strong expression of c-kit (CD117) in discrete mononuclear cells
(arrows) of the upper dermis; magnification 1:100 (D) and 1:400 (E). (F)
Giemsa staining revealing an increased number of mast cells (arrows) in the
upper dermis of lesional skin; magnification 1:400.
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